文献速递白血病

Cusatuzumab联合阿扎胞苷治疗不适合强化化疗的新诊断急性髓系白血病(CULMINATE):随机、2期剂量优化研究第一部分

Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.
PubMed 文献 · Lancet Haematol · 2023-01-01

CULMINATE研究第一部分在七个国家40家医院纳入103例不适合强化化疗的新诊断急性髓系白血病成人患者,随机分配至cusatuzumab 10 mg/kg或20 mg/kg联合阿扎胞苷治疗。10 mg/kg组完全缓解率为12%(6/51,95%CI 6-23),20 mg/kg组为27%(14/52,95%CI 17-40)。研究未对两个剂量组进行正式统计学比较,但作者认为20 mg/kg联合阿扎胞苷是后续研究的最佳剂量。

要点

  • Cusatuzumab 20 mg/kg联合阿扎胞苷组完全缓解率为27%,10 mg/kg组为12%。
  • 两组3级及以上治疗中出现的不良事件相似,包括血小板减少、贫血和中性粒细胞减少。
  • 研究第一部分未设计正式比较两个剂量组的疗效。

核心结论

  • 尽管研究第一部分未设计正式比较两个剂量组的疗效,但迄今cusatuzumab研究的全部临床数据表明,cusatuzumab 20 mg/kg联合阿扎胞苷是后续研究的最佳剂量。
  • 一项研究cusatuzumab联合维奈克拉和阿扎胞苷三药联合方案的1b期研究正在进行中(NCT04150887)。

研究设计与样本

  • 随机、2期、开放标签、剂量优化研究,在七个国家40家医院和中心纳入年龄18岁及以上、新诊断急性髓系白血病且不适合强化化疗、东部肿瘤协作组评分为0-2分的成人患者。
  • 2019年8月30日至2020年2月25日期间共入组103例患者,按1:1随机分配至cusatuzumab 10 mg/kg(n=51)或20 mg/kg(n=52),第3天和第17天静脉给药,联合阿扎胞苷75 mg/m2第1-7天皮下或静脉给药,28天为一周期。
  • 主要疗效结局为意向治疗组的完全缓解率;两个剂量队列独立评估,未进行组间统计学比较;安全性分析纳入所有接受一剂研究药物的患者。
  • 研究第二部分原计划为单臂扩展,评估第一部分选定的cusatuzumab剂量联合阿扎胞苷(主要假设完全缓解率≥35% vs 无效假设20%),但因急性髓系白血病治疗格局变化使入组在临床不可行,研究在第一部分结束时停止。
  • 试验注册于ClinicalTrials.gov,NCT04023526。

主要发现

  • 103例患者中57例(55%)为男性,46例(45%)为女性;78例(76%)为白人,1例(1%)为亚裔,24例(23%)未报告种族。
  • 中位随访时间为7.2个月(IQR 10.7个月)。
  • 10 mg/kg组完全缓解率为12%(6/51,95%CI 6-23),20 mg/kg组完全缓解率为27%(14/52,95%CI 17-40)。
  • 3级及以上治疗中出现的不良事件在cusatuzumab 10 mg/kg组(n=51)和20 mg/kg组(n=51)相似,包括血小板减少(24例[47%] vs 29例[57%])、贫血(24例[47%] vs 17例[33%])和中性粒细胞减少(两组均为20例[39%])。
  • 严重治疗中出现的不良事件两组相似(44例[86%] vs 40例[78%]);导致死亡的治疗相关不良事件两组均有报告(10 mg/kg组3例[6%] vs 20 mg/kg组1例[2%]),报告的死因为肺炎(n=2)和感染性休克(n=2)。

关键数值与推荐

  • 10 mg/kg组完全缓解率12%(6/51,95%CI 6-23),20 mg/kg组完全缓解率27%(14/52,95%CI 17-40)。

临床怎么用

  • 作者认为cusatuzumab 20 mg/kg联合阿扎胞苷是后续研究的最佳剂量。
  • 研究第一部分未设计正式比较两个剂量组的疗效。

局限性

  • 研究第一部分未设计正式比较两个剂量组的疗效。
  • 因急性髓系白血病治疗格局变化使入组在临床不可行,研究在第一部分结束时停止,未进行第二部分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cusatuzumab, a high-affinity anti-CD70 antibody, has shown preliminary activity as a treatment for acute myeloid leukaemia when combined with azacitidine. We aimed to determine the optimum dose for future trials of cusatuzumab in combination with azacitidine in patients with previously untreated acute myeloid leukaemia who are not eligible for intensive chemotherapy. METHODS: In this randomised, phase 2, open-label, dose-optimisation study we enrolled adult patients aged 18 years or older with newly diagnosed acute myeloid leukaemia not eligible for intensive chemotherapy, and with Eastern Cooperative Oncology Group scores of 0-2, from 40 hospitals and centres across seven countries. In part one of the trial, participants were randomly allocated 1:1 to 10 mg/kg or 20 mg/kg intravenous cusatuzumab on days 3 and 17, combined with subcutaneous or intravenous azacitidine 75 mg/m2 on days 1-7 in 28-day cycles. The primary efficacy outcome was the rate of complete remission in the intention-to-treat group. The two dose cohorts were evaluated independently without between-cohort statistical comparison. Safety analyses were performed in all patients who received one dose of study drug. Part two of the trial was planned to be a single-arm expansion to evaluate cusatuzumab plus azacitidine at the cusatuzumab dose level selected in part one (primary hypothesis ≥35% rate of complete remission vs null hypothesis of 20%); however, changes in the acute myeloid leukaemia treatment landscape during this trial made it unlikely that enrolment to part two of the study would be clinically feasible, so the study stopped at the end of part one. The trial was registered at ClinicalTrials.gov, NCT04023526. FINDINGS: 103 patients were enrolled between Aug 30, 2019, and Feb 25, 2020, and randomly assigned to either cusatuzumab 10 mg/kg (n=51) or 20 mg/kg (n=52). Median follow-up was 7·2 months (IQR 10·7 months). 57 of 103 (55%) patients were male and 46 (45%) patients were female, 78 (76%) were White, one (1%) was Asian, and 24 (23%) did not report their race. In the 10 mg/kg group, complete remission rate was 12% (six of 51 patients; 95% CI 6-23) and in the 20 mg/kg group was 27% (14 of 52; 17-40). Grade 3 or worse treatment-emergent adverse events (TEAEs) were similar between the cusatuzumab 10 mg/kg (n=51) and 20 mg/kg (n=51) cohorts and included thrombocytopenia (24 patients [47%] vs 29 [57%]), anaemia (24 [47%] vs 17 [33%]), and neutropenia (20 [39%] in both cohorts). Serious TEAEs were also similar in the two cohorts (44 [86%] vs 40 [78%]). Treatment-related TEAEs leading to death were reported in both groups (three patients [6%] in the 10 mg/kg group vs one patient [2%] in the 20 mg/kg group); the reported causes of death were pneumonia (n=2) and septic shock (n=2). INTERPRETATION: Although part one of this study was not designed to formally compare the two dose cohorts for efficacy, the totality of clinical data for cusatuzumab studies performed to date indicate that cusatuzumab 20 mg/kg plus azacitidine represents the optimal dose for further studies. A phase 1b study investigating the triple combination of cusatuzumab with venetoclax and azacitidine is underway (NCT04150887). FUNDING: Janssen Research & Development and argenx.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Pabst T, Papayannidis C, Demirkan F, et al. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study. Lancet Haematol. 2023. PMID: 37914483. doi:10.1016/S2352-3026(23)00207-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。